- Medical schools to start teaching MAHA approach to nutrition.
- What to know about vaccine mandates, vaccine lawsuits and compensation for vaccine injuries.
- Disappointment at TrumpRx: later, the site has only 44 of the 24,000 prescription drugs that federal regulators have approved.
- If we defunded the police, could we have law enforcement without them?
- More than 40 percent of heath care spending is for shoppable services.
Category: Cost of Healthcare
The FDA is Increasingly Skeptical of Therapies for Rare Diseases
The FDA under Trump has consistently maintained its stated goal of removing bureaucratic obstacles to drug approval. FDA commissioner, Marty Makary, announced steps to speed the approval of new drugs, including allowing one well-designed clinical trial rather than two or more trials to show efficacy. Yet, drug companies continue to claim inconsistent guidelines, endpoints changed and a skeptical agency when it comes to rare disease therapies. Recently drugmakers have complained the FDA moved the goalposts, after agreeing to them.
Friday Links – 6 March 2026
- Medicare Advantage enrollees have fewer inpatient hospital stays and are less likely to be discharged to any postacute care setting.
- Capretta on surprise medical bills. He seems to endorse the Goodman solution.
- Is ivermectin effective against covid? What ChatGPT gets wrong.
- What to know about Trump accounts.
- What a “hospital death spiral” looks like.
Donor Organs are Scarce Only Because there is No Free Market for Organ Donations
According to the United Network for Organ Sharing, there were more than 48,000 transplants in 2024 compared to around 108,000 on transplant waiting lists. The demand for organs far exceeds the supply. The reason organs are scarce is because living people and their family members have little reason to donate knowing there is little in it for them. It seems the only party involved in the organ transplant industry who does not profit from the process is the donor.